Details

Autor(en) / Beteiligte

• Kim, Seok Jin
• Kim, Kihyun
• Kim, Byung Soo
• Kim, Chul Yong
• Suh, Cheolwon
• Huh, Jooryung
• Lee, Sang-Wook
• Kim, Jin Seok
• Cho, Jaeho
• Lee, Gyeong-Won
• Kang, Ki Mun
• Eom, Hyeon Seok
• Pyo, Hong Ryull
• Ahn, Yong Chan
• Ko, Young Hyeh
• Kim, Won Seog

Titel

Phase II Trial of Concurrent Radiation and Weekly Cisplatin Followed by VIPD Chemotherapy in Newly Diagnosed, Stage IE to IIE, Nasal, Extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma Study

Ist Teil von

• Journal of clinical oncology, 2009-12, Vol.27 (35), p.6027-6032

Ort / Verlag

United States: American Society of Clinical Oncology

Erscheinungsjahr

2009

Quelle

MEDLINE

Beschreibungen/Notizen

• On the basis of the benefits of frontline radiation in early-stage, extranodal, natural killer (NK)/T-cell lymphoma (ENKTL), we conducted a phase II trial of concurrent chemoradiotherapy (CCRT) followed by three cycles of etoposide, ifosfamide, cisplatin, and dexamethasone (VIPD). Thirty patients with newly diagnosed, stages IE to IIE, nasal ENKTL received CCRT (ie radiation 40 to 52.8 Gy and cisplatin 30 mg/m(2) weekly). Three cycles of VIPD (etoposide 100 mg/m(2) days 1 through 3, ifosfamide 1,200 mg/m(2) days 1 through 3, cisplatin 33 mg/m(2) days 1 through 3, and dexamethasone 40 mg days 1 through 4) were scheduled after CCRT. All patients completed CCRT, which resulted in 100% response that included 22 complete responses (CRs) and eight partial responses (PRs). The CR rate after CCRT was 73.3% (ie, 22 of 30 responses; 95% CI, 57.46 to 89.13). Twenty-six of 30 patients completed the planned three cycles of VIPD, whereas four patients did not because they withdrew (n = 2) or because they had an infection (n = 2). The overall response rate and the CR rate were 83.3% (ie; 25 of 30 responses; 95% CI, 65.28 to 94.36) and 80.0% (ie, 24 of 30 responses; 95% CI, 65.69 to 94.31), respectively. Only one patient experienced grade 3 toxicity during CCRT (nausea), whereas 12 of 29 patients experienced grade 4 neutropenia. The estimated 3-year, progression-free and overall survival rates were 85.19% (95% CI, 72.48 to 97.90) and 86.28% (95% CI, 73.97 to 98.59), respectively. Patients with newly diagnosed, stages IE to IIE, nasal ENKTL are best treated with frontline CCRT.